Olema PharmaceuticalsOLMA
OLMA
About: Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Employees: 88
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
19,222% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $9K
311% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 9
36% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 39
21.97% more ownership
Funds ownership: 102.42% [Q3] → 124.4% (+21.97%) [Q4]
20% more funds holding
Funds holding: 130 [Q3] → 156 (+26) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
41% less capital invested
Capital invested by funds: $700M [Q3] → $415M (-$285M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
396%
upside
Avg. target
$28
449%
upside
High target
$30
495%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 21% 1-year accuracy 34 / 160 met price target | 495%upside $30 | Buy Reiterated | 28 Apr 2025 |
JP Morgan Anupam Rama 18% 1-year accuracy 11 / 60 met price target | 456%upside $28 | Overweight Maintained | 28 Mar 2025 |
Oppenheimer Matthew Biegler 7% 1-year accuracy 2 / 27 met price target | 396%upside $25 | Outperform Reiterated | 19 Mar 2025 |
Financial journalist opinion
Based on 5 articles about OLMA published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer (NSCLC) models. These findings are being presented in a late-breaking poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.
Positive
Zacks Investment Research
5 days ago
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Negative
Zacks Investment Research
2 weeks ago
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)
The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Seeking Alpha
3 weeks ago
Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market
Olema Pharmaceuticals's palazestrant shows promise in late-stage trials for metastatic breast cancer, with potential FDA approval and commercial launch by 2027. Strong liquidity with $139.5 million in cash and $294.6 million in marketable securities, providing a cash runway of 4-4.5 years. Despite competition in the SERD space, OLMA's valuation is low at $200 million, suggesting potential for significant upside.
Neutral
GlobeNewsWire
3 weeks ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 5 new employees to purchase an aggregate of 64,900 shares of the Company's common stock, effective as of April 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer models in a late-breaking session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. Poster Presentation Details Title: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models Poster/Abstract: LB166 Session: Late-Breaking Research: Tumor Biology 2 Date/Time: April 28, 2025, from 9:00am-12:00pm CT / 10:00am-1:00pm ET Presenter: Dr. Gopinath S.
Neutral
GlobeNewsWire
1 month ago
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
SAN FRANCISCO, March 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
Olema Oncology Appoints Shawnte M. Mitchell, J.D.
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary.
Neutral
GlobeNewsWire
2 months ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 285,000 shares of the Company's common stock, effective as of February 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™